

Haematologica  
HAEMATOL/2015/127126  
Version 3

Assessing patients' anticoagulation preferences for the treatment of  
cancer-associated thrombosis using conjoint methodology

Disclosures: SN has received honoraria for lectures (LEO Pharma, Pfizer, Bristol Meyers Squibb, Boehringer Ingelheim), advisory boards (Pfizer, Bristol Meyers Squibb, Sanofi Aventis) & grant support (Pfizer, LEO Pharma). AMat has received honoraria for lectures (AMGEN, Boehringer Ingelheim, Behring, Bristol Myers Squibb, GlaxoSmithKline, LEO Pharma, Roche), advisory boards (AMGEN, GlaxoSmithKline, Baxter, LEO Pharma, Boehringer Ingelheim) & grant support (LEO Pharma, Merck Serono, Roche). AMar has received honoraria for lectures (LEO Pharma and Pfizer) advisory (Bristol Myers Squibb, LEO Pharma and Pfizer) and grant support (LEO Pharma and Pfizer) including Conference Sponsorship (LEO Pharma Pfizer and Bristol Myers Squibb). GP is employed by Kantar Health GmbH, which conducted the study on behalf of LEO Pharma A/S. MH is an employee at LEO Pharma A/S. The study is sponsored by LEO Pharma A/S

Contributions: SN and MH conceived the study. All authors contributed to the study design, data analysis and manuscript preparation. GP was responsible for study design, data collection and primary analysis.